e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Various backgrounds in diffuse parenchymal lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of azithromycin-predominant combined therapy on patients with diffuse panbronchiolitis
H. Li, Y. Zhou, F. Fan, X. Li, H. Yu (Shanghai, China)
Source:
Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Session:
Various backgrounds in diffuse parenchymal lung disease
Session type:
Thematic Poster Session
Number:
751
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Li, Y. Zhou, F. Fan, X. Li, H. Yu (Shanghai, China). Effect of azithromycin-predominant combined therapy on patients with diffuse panbronchiolitis. Eur Respir J 2009; 34: Suppl. 53, 751
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Diffuse panbronchiolitis
Source: Eur Respir J 2008; 32: 237-238
Year: 2008
Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis
Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases
Year: 2020
Effects of long-term humidification therapy in bronchiectasis patients and overlap (bronchiectasis/asthma)
Source: International Congress 2019 – Novel interventions and models of pulmonary rehabilitation
Year: 2019
Diffuse panbronchiolitis and mimickers of bronchiolitis
Source: Annual Congress 2004 - PG14 - Bronchiolitis in adults
Year: 2004
Efficacy of traditional and combined therapy in patients with sarcoidosis
Source: Eur Respir J 2003; 22: Suppl. 45, 234s
Year: 2003
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF
Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases
Year: 2021
The natural course of systemic sclerosis patients with interstitial lung involvement
Source: Eur Respir J 2005; 26: Suppl. 49, 336s
Year: 2005
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007
Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis
Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys
Year: 2021
Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 707s
Year: 2004
Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report
Source: Eur Respir J 2006; 28: Suppl. 50, 829s
Year: 2006
Long-term macrolides in diffuse interstitial lung diseases
Source: Eur Respir Rev, 26 (146) 170082; 10.1183/16000617.0082-2017
Year: 2017
Effect of ABPA treatment in severe asthma patients with acute and relapsed disease
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 721s
Year: 2005
Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis
Source: Eur Respir J 2001; 18: 753-757
Year: 2001
Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept